INTRODUCTION
The 4-aminoquinoline compounds, chloroquine (Aralen) and hydroxychloroquine (Plaquenil), have been used increasingly since the 1950s to treat a variety of conditions. 1 2 Despite an impressive number of potential side effects, these drugs have a remarkable safety record. 1 One significant side effect is retinal toxicity, which can lead to permanent and progressive vision loss even after the offending drug has been stopped. 2 While the pathogenesis of the retinopathy is not well established, it has been suggested that the drug affects the metabolism of the retinal pigment epithelial cells, which leads to pigment migration and ultimately photoreceptor degeneration. 3 Hydroxychloroquine has been widely accepted as the safer alternative, although the two drugs have never been directly compared. 1 2 Nonetheless, hydroxychloroquine has been used more frequently over the past few decades. 1 3 Retinopathy from hydroxychloroquine is exceedingly rare. While it has been estimated that over 150 000 people take hydroxychloroquine in the USA, only 47 cases of true hydroxychloroquine retinopathy had been reported between 1960 and 2005. 3 4 Screening for retinopathy has proven to be challenging because of the rarity of this condition coupled with the late onset of symptoms and a lack of awareness among patients and physicians. The purposes of this study were to assess the characteristics of patients with hydroxychloroquine retinopathy at our institution and to review the current guidelines regarding screening and management of this condition. To our knowledge, this is the largest case series of hydroxychloroquine retinopathy ever reported.
PATIENTS AND METHODS
The Institutional Review Board of the Emory University School of Medicine approved this study. We reviewed the medical records of consecutive patients with hydroxychloroquine retinopathy between 1 January 2004 and 31 December 2008. A total of seven patients were included for analysis. Every patient, except for patient 6, had been referred to our institution by community ophthalmologists for further diagnostic testing based on a suspicion of retinal toxicity from hydroxychloroquine. Every patient, except for one, had already stopped taking hydroxychloroquine by the time of presentation because of this suspicion. The frequency of their previous eye examinations and the records from these visits were not available for our review.
The demographic information, age at presentation, symptoms, past ocular and medical history, family history and a detailed medication history were recorded for each patient. The daily drug dosage was calculated according to each patient's lean body weight. 5 The lean body weight for men, in kilograms, is equal to 50 plus 2.3 kg for every inch over 5 feet in height. 5 The lean body weight for women, in kilograms, is equal to 45.5 plus 2.3 kg for every inch over 5 feet in height. 5 Snellen visual acuities, funduscopic features, visual field results, electroretinography findings and fundus autofluorescence patterns were also recorded. Amsler grid testing was used in some but not all patients. Colour vision was assessed by using Ishihara tests for colour deficiency (Kanehara & Co. Ltd., Tokyo, Japan). A patient was considered to have significant colour vision impairment if they missed more than half of the colour plates in at least one eye, and mild colour vision impairment if they missed less than half of the colour plates in at least one eye.
RESULTS
The patient demographics and pertinent clinical information are included in tables 1 and 2. Every patient was female, with a mean age of 61.3 years at presentation. Every patient was treated with 400 mg of hydroxychloroquine per day. Only one patient had renal insufficiency (patient 4), and none had hepatic disease. With the exception of patient 7, every patient had normal or near-normal body mass indices. The mean daily dose of hydroxychloroquine according to lean body weight was 8.2 mg/kg/day (range 6.8e13.6 mg/kg/day), and the mean duration of usage was 16.3 years (range 8.5e30 years). The mean cumulative dose of hydroxychloroquine was 2377 g (range 1241e4380 g). The mean visual acuity for all eyes at presentation was 20/30, and every patient maintained visual acuity within two lines of their presenting visual acuity at last follow-up. The mean follow-up time was 21 months (range 0e56 months). The classic 'bull's eye' appearance of the central macula was seen in three patients (patients 1, 5 and 6). The other four patients had a stippled pattern of hyperpigmentation in the central macula. The fundus abnormalities were bilateral in all cases.
Visual-field defects were seen in every patient. The visual-field defects remained stable in every patient except patient 3, who experienced improvement in visual acuity, colour vision and visual-field parameters. Figure 1 shows the colour fundus photographs, fundus autofluorescence photographs and Humphrey 10e2 visual field results for patient 5.
Only one patient had significant ocular history (patient 6). This patient initially complained of decreased peripheral vision for the previous 8e9 years. Her medical history was significant for systemic lupus erythematosus, and she had been taking hydroxychloroquine 400 mg/day for the previous 13 years. Of note, she reported that both her father and sister were legally blind from an unknown aetiology. Her funduscopic examination showed retinal vasculature attenuation, central macular retinal pigment epithelial mottling as well as mild cystoid macular oedema. There were no bone spicules noted on the fundus exam. Her Humphrey visual field showed a small central island of vision in each eye, and her electroretinogram showed mildly diminished cone responses and moderately diminished rod responses. A diagnosis of possible autosomal dominant rodecone dystrophy with cystoid macular oedema was made, and she was started on a trial of acetazolamide. She was lost to follow-up for 1 year, and she returned complaining of worsening vision in her right eye. Her vision at that time was 20/80 in the right eye and 20/50 in the left eye. There continued to be retinal pigment epithelial mottling in each eye, but no cystoid macular oedema was present. It was recommended that she decrease or stop her hydroxychloroquine at this time as a precautionary measure. Despite this recommendation, she continued to take her usual dose of 400 mg/day. One year later, her repeat electroretinogram showed worsening attenuation of both the rod and cone systems, and her Goldman visual field showed less than 58 of visual field in each eye. At her next follow-up appointment, 4 years after her initial presentation, she had developed a bull's eye maculopathy on her funduscopic examination and had indeed experienced a decline of visual function. At her last follow-up 10 months later, she had a slightly smaller island of visual field, and her electroretinogram had remained stable.
Three patients exhibited significant colour vision impairment, three had mild colour vision impairment, and one patient had normal colour vision. Full field electroretinography was performed on four patients (patients 1, 2, 4 and 6), and all four patients had attenuated rod and cone function.
DISCUSSION
The purpose of this study was to assess the clinical characteristics of patients with hydroxychloroquine retinopathy at our institution. All of our patients exceeded the recommended daily allowance by lean body weight despite being treated with the usual dosage of 400 mg/day. While every patient maintained fairly good visual acuity, they all experienced significant visualfield defects. Additionally, colour vision was affected in six patients. The visual outcomes remained stable for every patient except for patient 3 who experienced improvement in visual acuity, colour vision and visual-field parameters.
Retinal toxicity from hydroxychloroquine has been well recognised for many years. Bernstein classified retinal toxicity into premaculopathy and true retinopathy in 1983. 6 Patients with premaculopathy were generally asymptomatic and had mild macular pigmentary changes. These patients did not have loss of visual acuity or visual-field defects. Bernstein later defined true retinopathy as the development of persistent paracentral or central visual-field scotoma to suprathreshold white stimuli and a duration of treatment of more than 9 months. 7 Every patient in our study satisfied this definition of true retinopathy. In 2006, Yam reviewed the 47 reported cases of true hydroxychloroquine retinopathy between 1960 and 2005. 3 While the results of our study are strikingly similar to those in this review, we found one notable difference. The mean cumulative dose for their patients was 997 g (range 12 to 2920 g), whereas the mean cumulative dose for our patients was 2377 g (range 1241 to 4380 g). They found that a few patients had been asymptomatic, but most had complained of symptoms such as difficulty reading, decreased vision, glare, flashing lights and metamorphopsias. Of the 22 patients in whom colour vision status was reported, 17 had some degree of impaired colour vision. All of the patients in our study were symptomatic on presentation to our institution, and six patients exhibited colour vision impairment. Interestingly, one of our patients demonstrated improved visual function after cessation of the drug. While only one of the patients in the review by Yam showed 'slight improvement,' we feel that our patient demonstrates the possibility of visual recovery after drug cessation. An important finding in our study was that every patient exceeded the recommended daily allowance, even though they were taking the usual dose of 400 mg of hydroxychloroquine per day. This evidence is unsettling, because it has been suggested that doses of 400 mg/day can be considered safe. 8 The most commonly quoted threshold for retinal toxicity is 6.5 mg/kg/ day. 3 9 10 If the usual daily dosage of 400 mg is considered, then a patient's lean body weight must be over 62 kg in order to be under this threshold for retinal toxicity. If it is assumed that a patient is of medium build, then women under 5 9 7 99 and men under 5 9 5 99 in height would exceed the recommended daily allowance by taking 400 mg a day. Another case series of patients with hydroxychloroquine retinopathy showed that three of the five patients had been taking 400 mg/day. 9 In this series, Browning comments that it would be useful to have a larger choice of pill sizes or possibly a liquid formulation so the drug dosage could be better titrated for each patient. 9 He also suggests that oversight by the dispensing pharmacist could help reduce overdosing. We agree that a larger dose selection would be beneficial, but a simpler way to titrate dosing is to use alternate day dosing. For example, a patient could take 400 mg one day and then 200 mg the next. Because the half life of hydroxychloroquine is long, this dosing regimen should not lead to exacerbation of symptoms on lower dosing days. There has been some discussion over how 'ideal' body weight should be calculated when considering daily dosages. Browning noted that he prefers to use the term top-normal body weight, which is the weight for a given height if one assumes a body mass index of 24. 11 He uses the table of body mass index, height and weight that is published on the National Heart, Lung and Blood Institute's website. 11 Easterbrook prefers to use the formula that we have used in this text, which he feels is more scientific because it is gender-specific.
11 Table 3 shows the height, weight, body mass indices and daily drug dosages according to top-normal body weight and lean body weight for our seven patients. Interestingly, when using top-normal body weight, only three of our patients exceeded the recommended daily drug allowance of 6.5 mg/kg/day. We prefer to use the formula for lean body weight because it is gender-specific and because it is more conservative. The more conservative approach may allow the screening physician to recommend slightly lower dosing to the prescribing physician, which may in turn lead to fewer cases of retinopathy.
The debate over proper screening recommendations stems from the rarity of the condition in combination with its devastating outcomes. The manufacturers recommend an ophthalmological examination with visual-field testing every 3 months. 12 This approach would potentially create an enormous burden on healthcare resources. 10 The American College of Rheumatology does not recommend a baseline ophthalmic examination unless the patient is over 40 years of age or has concomitant eye disease. 13 If the patient has demonstrated a clinical response to hydroxychloroquine after 6 months, then eye examinations should be performed every 6e12 months in the absence of risk factors, and more frequently if risk factors are present. 13 The risk factors they note are cumulative drug dosages greater than 800 g or daily dosages greater than 6.0 mg/kg/day, age greater than 70 years and the presence of renal or hepatic dysfunction. An overview of the screening recommendations of the American Academy of Ophthalmology (AAO) is shown in figure 2 . 10 According to these recommendations, patients need no special screening in the first 5 years of use if they are found to be low risk at baseline. Higher-risk patients need annual ophthalmic examinations with visual-field testing (Amsler grid or Humphrey 10e2 field test), and should be instructed to use the Amsler grid at home. The importance of patient counselling at each screening exam cannot be understated. Many of the patients in our study reported that they had routine eye exams, usually every 6 months, during the first few years of hydroxychloroquine use. However, because they did not understand the importance of their screening examinations, they failed to follow-up with their ophthalmologist until irreversible damage had occurred.
There have been several recent studies suggesting that multifocal electroretinography (mfERG) may be the key to early detection of hydroxychloroquine retinopathy.
14e18 The advantage of the mfERG is that it generates local responses topographically across the posterior pole. 10 It should be noted that the amplitude of the mfERG can vary up to 30%, which reduces its effectiveness for clinical decision-making. 14 19 Lyons and Severns, who developed a ring ratio analysis program for the mfERG, found a statistically significant difference in the mfERG patterns between patients with cumulative doses greater than 1250 g compared with those with cumulative doses less than 1250 g.
14 They concluded that mfERG ring ratios provide a clearly defined, quantitative measure for early detection of hydroxychloroquine toxicity. They recommended baseline mfERG testing in all patients on hydroxychloroquine and repeat testing when the patient had reached a cumulative dose of 400 g and then every 2 years thereafter.
While the findings of this study are exciting, they should be tempered with some practical concerns. First, there are not sufficient data yet to determine if patients who show early loss of retinal function on mfERG will ultimately experience clinically significant visual impairment. Stopping hydroxychloroquine because of mfERG abnormalities which suggest subclinical toxicity may actually cause more harm than good.
Marmor and Block have pointed out that hydroxychloroquine is an extremely effective drug and allows patients to avoid the side effects of alternative therapies such as corticosteroids or immunosuppressive agents. 20 21 Another concern is that the mfERG is not widely available currently. Also, because clinical retinal toxicity is so rare, the mfERG may have limited utility in routine screening when considering a costebenefit analysis. Nonetheless, screening regimens may change once the clinical efficacy of the mfERG for detecting early hydroxychloroquine retinopathy has been fully established.
There are several limitations to this study. This is a retrospective analysis which allows for the introduction of various types of bias. Also, because every patient was referred to our tertiary referral centre, selection bias towards more severe cases is possible. Ideally, further investigation would include a large prospective population-based study that included detailed medication histories, body mass index determination, masked fundus photography and visual field interpretation, as well as electroretinographic testing. This type of study would be costly, but could potentially save money if screening regimens were optimised and vision loss was prevented.
CONCLUSIONS
Hydroxychloroquine retinopathy, although rare, still exists despite current screening guidelines. Determining the daily dosage according to lean body weight is an important part of the risk stratification process. The optimal screening regimen remains to be established, but we believe that physicians should use risk stratification to help guide their screening strategies. Patients who are taking more than 6.5 mg/kg of hydroxychloroquine per day, those who have been using the medicine for greater than 5 years, those over the age of 60, and those who have high body fat content or concomitant renal or liver disease should be considered at higher risk and screened more frequently.
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